Paper Details

  1. Home
  2. Paper Details

Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial.

Author: , AnneseVito, BalzanoAntonio, CampieriMassimo, D'ArienzoAgesilao, GionchettiPaolo, IaquintoGaetano, LecisPier Enrico, MaieronRoberto, MangusoFrancesco, RizzelloFernando, ValpianiDaniela, VaroliGuido

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Beclomethasone dipropionate (BDP) administered as a rectal enema was efficacious and safe in patients with active ulcerative colitis (UC), without interfering with pituitary adrenal axis.
Paper Details　
Original Abstract of the Article :
GOALS: Therapy for active ulcerative colitis (UC) usually involves rectal formulations of corticosteroids (CS), which are characterized by the risk of systemic steroid-related adverse effects. BACKGROUND: To compare the efficacy and safety of the topically acting CS beclomethasone dipropionate (BDP...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/01.mcg.0000155124.74548.61

データ提供：米国国立医学図書館（NLM）

Topical Treatment of Ulcerative Colitis: A New Frontier in Inflammatory Bowel Disease Management

Ulcerative colitis, a chronic inflammatory bowel disease, can cause significant discomfort and disruption to daily life. This study investigates the efficacy and safety of topical treatments, specifically beclomethasone dipropionate (BDP) and mesalamine, for active ulcerative colitis (UC).

Topical Treatments for UC: Targeting Inflammation at the Source

The study found that both BDP and mesalamine, administered topically as enemas, were effective in reducing disease activity and achieving clinical remission in patients with distal active UC. These topical treatments offer a promising alternative to systemic corticosteroids, minimizing the risk of systemic side effects. This research is like finding a hidden spring in the desert of UC treatment – a source of relief and targeted therapy.

Managing UC: Finding the Right Path to Long-Term Health

This study highlights the potential of topical treatments for UC, offering a targeted approach to managing this inflammatory bowel disease. However, it's important to note that the study focused on distal UC, and further research is needed to evaluate the efficacy of these treatments in other forms of UC. Just as a camel adapts to the changing desert landscape, we must continue to explore and adapt treatment approaches for UC, finding the best solutions for each individual.

Dr.Camel's Conclusion

This study demonstrates the effectiveness of topical treatments, particularly BDP, in managing distal active UC. This research is a beacon of hope in the desert of UC treatment, offering a targeted and potentially safer alternative to systemic corticosteroids. It's a testament to the ongoing efforts of researchers to find innovative ways to manage inflammatory bowel diseases, providing a path toward improved quality of life for those living with UC.
Date :
  1. Date Completed 2005-07-18
  2. Date Revised 2019-08-17
Further Info :

Pubmed ID

15758622

DOI: Digital Object Identifier

10.1097/01.mcg.0000155124.74548.61

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.